International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 5 , Pages 1293-1303 , 1 April 2009

Larynx Preservation Clinical Trial Design: Key Issues and Recommendations—A Consensus Panel Summary

  • Jean-Louis Lefebvre, M.D.

      Affiliations

    • Département de Cancérologie Cervico-Faciale, Centre Oscar Lambret, Lille, France
    • Corresponding Author InformationReprint requests to: Jean-Louis Lefebvre, M.D., Département de Cancérologie Cervico–Faciale, Centre Oscar Lambret, 3 rue Frédéric Combemale, B.P. 307, F-59020, Lille, France. Tel: +33 3 2029 5531; Fax: +33 3 2029 5961
    • ,
  • K. Kian Ang, M.D.

      Affiliations

    • University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Larynx Preservation Consensus Panel

Received 7 August 2008 ,Revised 24 October 2008 ,Accepted 30 October 2008.

References 

  1. VALCSG (The Department of Veterans Affairs Laryngeal Cancer Study Group). Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685–1690
  2. Lefebvre J-L, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst. 1996;88:890–899
  3. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098
  4. Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx—induction cisplatin/5-FU and radiation therapy vs. concurrent cisplatin and radiation therapy vs. radiation therapy. [ASCO Annual Meeting Proc Part I, abstract] J Clin Oncol 2006. 2006;24(Suppl):5517
  5. Marur S, Forastiere AA. Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83:489–501
  6. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–1715
  7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  8. Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol. 2006;24:593–598
  9. Weber RS, Berkey BA, Forastiere A, et al. Outcome of salvage total laryngectomy following organ preservation therapy: The Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg. 2003;129:44–49
  10. Spaulding MB, Fischer SG, Wolf GT, et al. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol. 1994;12:1592–1599
  11. Bradford CR, Wolf GT, Carey TE, et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg. 1999;121:534–538
  12. Lefebvre J-L, Chevalier D, Luboinski B, et al. Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the EORTC 24891 trial. [ASCO Annual Meeting Proc (Post-Meeting Edition, abstract] J Clin Oncol. 2004;22(Suppl):5531
  13. Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998;34:224–228
  14. Calais G, Pointreau Y, Alfonsi M, et al. Induction chemotherapy for larynx preservation. Updated results of the GORTEC 2000-01 randomized trial comparing docetaxel + cisplatinum + fluorouracil (TPF) vs. cisplatinum + fluorouracil (PF). [Abstract] Eur J Cancer. 2007;5(Suppl):324
  15. Lefebvre J, Horiot J, Rolland F, et al. Phase III study on larynx preservation comparing induction chemotherapy and radiotherapy vs. alternating chemoradiotherapy in resectable hypopharynx and larynx cancers. EORTC protocol 24954-22950. [ASCO Annual Meeting Proc Part I, abstract] J Clin Oncol. 2007;25(Suppl):LBA6016
  16. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck. 2005;27:843–850
  17. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004;15:1179–1186
  18. Li XM, Wei WI, Guo XF, et al. Cervical lymph node metastatic patterns of squamous carcinomas of the upper aerodigestive tract. J Laryngol Otol. 1996;110:937–941
  19. Mendenhall WM, Parsons JT, Stringer SP, et al. Stage T3 squamous cell carcinoma of the glottic larynx: A comparison of laryngectomy and irradiation. Int J Radiat Oncol Biol Phys. 1992;23:725–732
  20. MacKenzie R, Franssen E, Balogh J, et al. The prognostic significance of tracheostomy in carcinoma of the larynx treated with radiotherapy and surgery for salvage. Int J Radiation Oncology Biol Phys. 1998;41:43–51
  21. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet. 2000;355:949–955
  22. Lefebvre J-L, Buisett E, Coche-Dequeant B, et al. Epilarynx: Pharynx or larynx?. Head Neck. 1995;17:377–781
  23. Eisbruch A, Thornton AF, Urba S, et al. Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer. J Clin Oncol. 1996;14:2322–2330
  24. Machtay M, Moughan J, Trotti A, et al. Pre-treatment and treatment related risk factors for severe late toxicity after chemo-RT for head and neck cancer: An RTOG analysis. [ASCO Annual Meeting Proc Part I, abstract] J Clin Oncol. 2006;24(Suppl):5500
  25. Rosen CA, Lee AS, Osborne J, et al. Development and validation of the voice handicap index-10. Laryngoscope. 2004;114:1549–1556
  26. Hogikyan ND, Sethuraman G. Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice. 1999;13:557–569
  27. Fung K, Lyden TH, Lee J, et al. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. Int J Radiat Oncol Biol Phys. 2005;63:1395–1399
  28. List MA, Rutherford JL, Stracks J, et al. Prioritizing treatment outcomes: Head and neck cancer patients vs. nonpatients. Head Neck. 2004;26:163–170
  29. Ronis DL, Duffy SA, Fowler KE, et al. Changes in quality of life over 1 year in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008;134:241–248
  30. Terrell JE, Ronis DL, Fowler KE, et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130:401–408
  31. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: Changes in demographics, patterns of care, and survival. Laryngoscope. 2006;116(Suppl 111):1–13
  32. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824–832
  33. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350–7356
  34. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006;12:5064–5073
  35. Mountzios G, Handra-Luca A, Hernandez J, et al. ERCC1 immunohistochemical expression and cancer-specific survival in patients with locally advanced squamous-cell carcinoma of the head and neck treated by cisplatin-based induction chemotherapy. [ASCO Annual Meeting Proc Part I, abstract] J Clin Oncol. 2007;25(Suppl):6011
  36. El-Naggar AK, Lippman SM, Johnson FM, et al. Correlation of Src activation with epithelial-mesenchymal transformation and aggressive features of head and neck squamous carcinoma. [ASCO Annual Meeting Proc Part I, abstract] J Clin Oncol. 2007;25(Suppl):6026
  37. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230–3237
  38. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552–2561
  39. Rosenbek JC, Robbins JA, Roecker EB, et al. A penetration–aspiration scale. Dysphagia. 1996;11:93–98
  40. Rademaker AW, Pauloski BF. Oropharyngeal swallow efficiency as a representative measure of swallowing function. J Speech Hearing Res. 1994;37:314–325
  41. Ludlow, CL, Sonies, BC, Humbert IA, et al. Validity and reliability of the Swallowing Safety Scale. Poster presentation at The Fifteenth Annual Dysphagia Research Society Meeting, March 8–10, 2007. Poster #59; Conference book p 362.
  42. List MA, Ritter-Sterr C, Lansky SB. A performance status scale for head and neck cancer patients. Cancer. 1990;66:564–569
  43. Chen AY, Frankowski R, Bishop-Leone J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: The M.D. Anderson Dysphagia Inventory. Arch Otolaryngol Head Neck Surg. 2001;127:870–876
  44. Karnell M, Melton J, Childes T, et al. Reliability of clinician-based (GRBAS and CAPE-V) and patient-based (V-RQOL and IPVI) documentation of voice disorders. J Voice. 2007;21:576–590
  45. Rosenthal DI, Mendoza TR, Chambers MS, et al. Measuring head and neck cancer symptom burden: The development and validation of the M.D. Anderson Symptom Inventory, head and neck module. Head Neck. 2007;29:923–931
  46. Bjordal K, Hammerlid E, Ahlnder-Elmqvist M, et al. Quality of life in head and neck cancer patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–H&N35. J Clin Oncol. 1999;17:1008–1019
  47. Op de Coul BM, Ackerstaff AH, van As CJ, et al. Quality of life assessment in laryngectomized individuals: Do we need additions to standard questionnaires in specific clinical research projects?. Clin Otolaryngol. 2005;30:169–175

 Sources of support: Sanofi-Aventis.

 Conflict of interest: Jean-Louis Lefebvre has potential conflicts of interest with Sanofi-Aventis, Merck Serono, IRX Therapeutics, and Genmab. K. Kian Ang has served on Advisory Boards of AstraZeneca, BMS, Imclone Systems Inc., Merck Serono, and Sanofi-Aventis. These commitments do not interfere with performing the task presented in the manuscript.

 To be published simultaneously in Head & Neck.

PII: S0360-3016(08)03693-6

doi: 10.1016/j.ijrobp.2008.10.047

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 5 , Pages 1293-1303 , 1 April 2009

Article Tools